CN107072973A - 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法 - Google Patents

含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法 Download PDF

Info

Publication number
CN107072973A
CN107072973A CN201580050984.7A CN201580050984A CN107072973A CN 107072973 A CN107072973 A CN 107072973A CN 201580050984 A CN201580050984 A CN 201580050984A CN 107072973 A CN107072973 A CN 107072973A
Authority
CN
China
Prior art keywords
levodopa
gel composition
pharmaceutical
carbidopa
entacapone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580050984.7A
Other languages
English (en)
Chinese (zh)
Inventor
罗杰·伯索伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lobsor Pharmaceuticals AB
Original Assignee
Lobsor Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451034A external-priority patent/SE538425C2/en
Application filed by Lobsor Pharmaceuticals AB filed Critical Lobsor Pharmaceuticals AB
Publication of CN107072973A publication Critical patent/CN107072973A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580050984.7A 2014-09-04 2015-09-04 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法 Pending CN107072973A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1451034A SE538425C2 (en) 2014-09-04 2014-09-04 Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
SE1451034-1 2014-09-04
SE1550344 2015-03-24
SE1550344-4 2015-03-24
PCT/SE2015/050939 WO2016036308A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Publications (1)

Publication Number Publication Date
CN107072973A true CN107072973A (zh) 2017-08-18

Family

ID=55440194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050984.7A Pending CN107072973A (zh) 2014-09-04 2015-09-04 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法

Country Status (16)

Country Link
US (5) US10071069B2 (enExample)
EP (3) EP3782617B1 (enExample)
JP (2) JP6622310B2 (enExample)
CN (1) CN107072973A (enExample)
AU (3) AU2015312430B2 (enExample)
CA (2) CA3175785A1 (enExample)
DK (2) DK3782617T3 (enExample)
ES (2) ES2973289T3 (enExample)
FI (1) FI3782617T3 (enExample)
HR (2) HRP20240314T1 (enExample)
HU (2) HUE052857T2 (enExample)
PL (2) PL3782617T3 (enExample)
PT (2) PT3188725T (enExample)
RS (1) RS65337B1 (enExample)
SI (2) SI3188725T1 (enExample)
WO (1) WO2016036308A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643493A (zh) * 2020-05-26 2020-09-11 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
CN112261940A (zh) * 2018-03-23 2021-01-22 劳波索尔制药有限公司 用于治疗神经退行性疾病的药物组合物的连续施用
TWI892226B (zh) * 2018-12-18 2025-08-01 美商美國禮來大藥廠 用於治療多巴胺性cns病症之ly3154207劑量療法
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
RU2017120184A (ru) * 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US20180021280A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and Carbidopa Intestinal Gel and Methods of Use
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
WO2018146194A1 (en) 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin
CN111902136A (zh) * 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 用于预防和/或治疗肥胖症和相关代谢性疾病的托卡朋
EP3593819A1 (en) 2018-07-10 2020-01-15 Medday Pharmaceuticals Compositions for therapeutic uses containing 5-htp and carbidopa
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
WO2022158991A1 (en) * 2021-01-20 2022-07-28 Bial-Portela & Ca., S.A. Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1845728A (zh) * 2003-08-29 2006-10-11 转化医药公司 药物组合物和使用左旋多巴和卡比多巴的方法
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴
CN102438587A (zh) * 2009-05-19 2012-05-02 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004348D0 (en) 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
HK1041441A1 (zh) * 1998-11-10 2002-07-12 Teva Pharmaceutical Industries, Ltd. 包含l-多巴乙酯的可分散组合物
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20060222703A1 (en) 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
SE538425C2 (en) 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1845728A (zh) * 2003-08-29 2006-10-11 转化医药公司 药物组合物和使用左旋多巴和卡比多巴的方法
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴
CN102438587A (zh) * 2009-05-19 2012-05-02 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C WARREN OLANOW ET AL: "Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease:a randomised, controlled, double-blind, double-dummy study", 《LANCET NEUROL》 *
巫世红等: "左旋多巴的强降解实验研究", 《中国药业》 *
袁莉娟等: "抗帕金森病药物恩他卡朋的药理作用与临床评价", 《中国新药杂志》 *
高博闻等: "儿茶酚-O-甲基转移酶抑制剂临床应用进展", 《现代生物医学进展》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112261940A (zh) * 2018-03-23 2021-01-22 劳波索尔制药有限公司 用于治疗神经退行性疾病的药物组合物的连续施用
CN112261940B (zh) * 2018-03-23 2024-02-27 劳波索尔制药有限公司 用于治疗神经退行性疾病的药物组合物的连续施用
TWI892226B (zh) * 2018-12-18 2025-08-01 美商美國禮來大藥廠 用於治療多巴胺性cns病症之ly3154207劑量療法
CN111643493A (zh) * 2020-05-26 2020-09-11 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
CN111643493B (zh) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Also Published As

Publication number Publication date
US10786472B2 (en) 2020-09-29
EP3782617B1 (en) 2024-01-03
CA2959307A1 (en) 2016-03-10
SI3188725T1 (sl) 2021-04-30
DK3782617T3 (da) 2024-03-04
HRP20240314T1 (hr) 2024-05-24
AU2015312430B2 (en) 2020-06-25
US11413262B2 (en) 2022-08-16
SI3782617T1 (sl) 2024-04-30
US20250041257A1 (en) 2025-02-06
JP2020045353A (ja) 2020-03-26
DK3188725T3 (da) 2021-01-18
US20180338944A1 (en) 2018-11-29
RS65337B1 (sr) 2024-04-30
AU2022200291B2 (en) 2024-01-25
AU2020239682B2 (en) 2021-12-23
JP6622310B2 (ja) 2019-12-18
EP3782617A1 (en) 2021-02-24
CA2959307C (en) 2023-03-28
HUE052857T2 (hu) 2021-05-28
PT3188725T (pt) 2021-01-27
PL3782617T3 (pl) 2024-06-24
PT3782617T (pt) 2024-02-29
PL3188725T3 (pl) 2021-08-02
EP3188725A4 (en) 2018-04-25
US20170231937A1 (en) 2017-08-17
ES2844500T3 (es) 2021-07-22
WO2016036308A1 (en) 2016-03-10
US10071069B2 (en) 2018-09-11
EP3188725B1 (en) 2020-10-28
AU2022200291A1 (en) 2022-02-10
US20210023033A1 (en) 2021-01-28
CA3175785A1 (en) 2016-03-10
JP6889231B2 (ja) 2021-06-18
FI3782617T3 (fi) 2024-03-13
AU2020239682A1 (en) 2020-10-15
US12156858B2 (en) 2024-12-03
AU2015312430A1 (en) 2017-03-30
EP4356907A1 (en) 2024-04-24
ES2973289T3 (es) 2024-06-19
HUE066097T2 (hu) 2024-07-28
US20220362193A1 (en) 2022-11-17
HRP20210025T1 (hr) 2021-03-05
JP2017527623A (ja) 2017-09-21
EP3188725A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
US12156858B2 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US10555922B2 (en) Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20250213518A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
HK40110793A (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
HK40044749B (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
HK40044749A (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
JPWO2019182506A5 (enExample)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818

WD01 Invention patent application deemed withdrawn after publication